Riskpilot← Back to searchSign inGet full accessROS Therapeutics Holding ApS
APSActiveCVR 39507056Ole Maaløes Vej 3Activities of holding companies · NACE 6421Est. 2018— employees
Revenue 2024
DKK -13K
+3% vs 2023
EBITDA margin
100.0%
-3% vs 2023
Equity ratio
-1383.0%
Financial strength
Net profit 2024
DKK -14K
-4% vs 2023
| Revenue | DKK -13K | +3% |
| EBITDA | DKK -13K | -3% |
| Net profit | DKK -14K | -4% |
| Total assets | DKK 19K | -29% |
| Equity | DKK -256K | -5% |
| Employees | — | — |
Legal name
ROS Therapeutics Holding ApS
CVR number
39507056
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
23. april 2018
Share capital
DKK 100.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen.
Company purpose
Selskabets formål er at investere samt anden virksomhed, der står i forbindelse hermed.
Address
Ole Maaløes Vej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -12 | -12 | -12 | -12 | -13 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -12 | -12 | -12 | -12 | -13 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -12 | -12 | -12 | -12 | -13 |
| Net financials | 4.000 | -4.273 | -5 | -5 | -6 |
| Profit before tax | 3.988 | -4.285 | -18 | -18 | -18 |
| Tax | -3 | -1 | -4 | -4 | -4 |
| Net profit | 3.990 | -4.285 | -14 | -14 | -14 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4.284 | 34 | 35 | 26 | 19 |
| Equity | 4.056 | -225 | -229 | -243 | -256 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 228 | 259 | 264 | 269 | 275 |
| Total debt | 228 | 259 | 264 | 269 | 275 |
EBITDA margin
-1287500.0%
This company
15.8%
Market median
-8148834% vs market
20202024
Equity ratio
-1383.0%
This company
38.2%
Market median
-3720% vs market
20202024
Return on equity
-1434200.0%
This company
18.4%
Market median
-7794665% vs market
20202024
Net profit margin
-1434200.0%
This company
8.1%
Market median
-17706273% vs market
20202024
Asset turnover
-0.70×
This company
1.12×
Market median
-163% vs market
20202024
Debt / equity
1.07×
This company
0.62×
Market median
-73% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HD Management | Management | 2018 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Board of Directors | 2018 – 2019 | |
| Board of Directors | 2018 – 2018 | |
| Board of Directors | 2018 – 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 66.67–89.99% | 66.67–89.99% | 2018 | |
| Company | 10–14.99% | 10–14.99% | 2020 | |
| Company | 5–9.99% | 5–9.99% | 2023 | |
| Company | 10–14.99% | 10–14.99% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SPORCON LIFESCIENCE ADVISORS ApS
ROS Therapeutics Holding ApS Board members of ROS Therapeutics Holding ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hanne Damgaard Jensen | Management | 0 companies |
| Mads Hartvig Clausen | Board of Directors | 0 companies |
| Christian Philip Hansen | Board of Directors | 0 companies |
| Jon Bondebjerg | Board of Directors | 0 companies |